Latest Conference

In a study of hospitalized patients across Europe, oritavancin (MIC50/MIC90, 0.03/0.06 mg/L) inhibited all S aureus isolates at ≤0.12 mg/L (susceptible breakpoint).

Ignacio Martin-Loeches, MD, PhD, discusses the efficacy outcomes of the ASPECT-NP trial evaluating ceftolozane/tazobactam for the treatment of nosocomial pneumonia.

What is the key to success that helped a Spanish hospital achieve an 80% reduction in global incidence of catheter-related bloodstream infections and sustain it over an 8-year period?

Jose Arribas, MD, discusses the challenges in the field of long-acting injectable therapy for the treatment, management, and even prevention of HIV.

A large percentage (96%) of health care worker respondents reported feeling confident in their knowledge of antibiotic resistance, but only 60% answered the 7 key questions correctly.

In a symposium at ECCMID 2019, Giovanni Rezza, MD, highlighted the growth of tropical outbreaks occurring in Europe and discussed how warmer temperatures may lead to more frequent tropical outbreaks.

After receiving treatment with ibrexafungerp, a patient with esophageal candidiasis gradually improved and by day 54 he was completely asymptomatic.

Investigators on the CapU3 study concluded that urinary HPV testing may be a good alternative to Pap smear for some women.

An 18-year retrospective cohort study of 130 hospitals in the US Veterans Health Administration system revealed a significant reduction in cases of hospital-onset candidemia. But what caused the drop?

MDROs were detected in 334 (22%) curtain cultures from 6 skilled nursing facilities in southeast Michigan.

Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.

Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.

Paul Sax, MD, names the DISCOVER study as one of the highlights of CROI 2019.

Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women.

Contagion® will be heading to Amsterdam, Netherlands, on Saturday, April 13, 2019, to report on the annual European Congress of Clinical Microbiology and Infectious Diseases conference.

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

PrEP isn’t covered by health insurance in Germany, and non-prescription use of the HIV preventive is common. But is it safe?

A survey of MSM and transgender women found that diverse formulations and regimens for PrEP, such as long-acting injectables and “on-demand” PrEP, could increase uptake and persistence.

Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

Paul Drain, MD, MPH, explains how point-of-care viral load testing was successful in providing rapid results to patients in a South African-based study.

A communitywide HIV prevention package including in-home testing and antiretroviral therapy reduces new infections, according to a study from the HIV Prevention Trials Network.

CROI 2019 was held March 4-7, 2018, in Seattle, Washington. The conference featured results of new studies on a variety of HIV topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting.

Kavita Misra, PhD, MPH, explains how health care providers can help prevent PrEP resistance from growing by increasing screening for acute HIV infection.